Polyglutamine Aggregation Inhibitor, PGL-137 (CAS 943-04-4)
QUICK LINKS
Polyglutamine Aggregation Inhibitor, PGL-137, is a chemical compound that has emerged as a noteworthy subject in scientific exploration due to its capacity to impede the aggregation of polyglutamine proteins, which are linked to several neurodegenerative disorders, including Huntington′s disease. This compound is categorized under aggregation inhibitors, aiming to halt the improper clumping and accumulation of polyglutamine proteins, a process implicated in the development of neurodegenerative conditions. Polyglutamine Aggregation Inhibitor, PGL-137 operates by interacting with polyglutamine proteins, preventing the formation of harmful aggregates and, as a result, could potentially mitigate toxicity and slow the advancement of neurodegeneration.
Polyglutamine Aggregation Inhibitor, PGL-137 (CAS 943-04-4) References
- Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. | Heiser, V., et al. 2002. Proc Natl Acad Sci U S A. 99 Suppl 4: 16400-6. PMID: 12200548
- The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington's Disease. | Ahamad, S. and Bhat, SA. 2022. J Med Chem. 65: 15993-16032. PMID: 36490325
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Polyglutamine Aggregation Inhibitor, PGL-137, 10 mg | sc-204208 | 10 mg | $184.00 |